摘要
目的探讨人类X射线交错互补修复基因1(XRCC1)单核苷酸多态性(SNP)与非小细胞肺癌(NSCLC)铂类药物化疗后预后的关系。方法采用MALDI-TOF-MS法检测204例经病理学确诊的接受铂类药物化疗的晚期NSCLC患者XRCC1(399)的基因型,并随机抽取5%的样本进行基因测序来验证该方法的准确性。比较不同基因型与铂类药物化疗后生存期的关系。结果 204例NSCLC患者中,部分缓解61例,疾病稳定116例,疾病进展27例;治疗有效率为29.9%,无效率为70.1%。携带XRCC1(399)G/G、G/A+A/A基因型的NSCLC患者铂类化疗后有效率分别为36.9%(38/103)和22.8%(23/101),两者比较差异有统计学意义(P<0.05)。XRCC1(399)G/G基因型患者对顺铂类药物的敏感性是G/A+A/A基因型患者的1.983倍(95%可信区间(CI):1.073~3.662,P=0.028)。携带XRCC1(399)G/G、G/A+A/A基因型的NSCLC患者铂类化疗后中位生存期(MST)、1年生存率及2年生存率分别为12.0月、52.4%、11.7%和10.0月、37.6%、3.0%,两者比较差异均有统计学意义(P<0.05)。结论 XRCC1(399)基因多态性与晚期NSCLC患者铂类药物化疗后的生存期有显著相关性,有可能成为铂类药物化疗后生存期的预测指标。
Objective To investigate the relationship between genetic polymorphisms of XRCC1 and survival of patients with advanced non-small cell lung cancer( NSCLC) treated with platinum-based chemotherapy. Methods A total of 204 patients with advanced NSCLC were routinely treated by platinum-based chemotherapy. The genotypes were analyzed by MALDITOF-MS method using DNA samples isolated from peripheral blood before treatment. Besides,5% of the samples were extracted randomly for sequencing to test the accuracy of this method. The association between SNPs of XRCC1( 399) and prognosis to platinum-based chemotherapy in the patients with advanced NSCLC was analyzed. Results Of 204 patients,61 achieved partial response,116 achieving stable response,and 27 having progressive disease. The overall effective rate was 29. 9%( 61 /204), and the ineffective rate was 70. 1%( 143 /204). The effective rates of patients with XRCC1( 399) G/ G genotype and G/ A + A/ A genotype were 36. 9%( 38 /103) and 22. 8%( 23 /101),respectively( P < 0. 05). The sensitivity to DDP of XRCC1( 399) G/ G allele carriers was 1. 983-fold of that of G/ A + A/ A allele carriers( 95% confidence interval CI: 1. 073 ~ 3. 662,P = 0. 028). Median survival time,1-year survival and 2-year survival rates of patients with XRCC1( 399) G/ G genotype and G/ A + T / T genotype were 12. 0 months,52. 4% and 11. 7% and 10. 0 months,37. 6% and 3.0%,respectively( P < 0. 05). Conclusions Polymorphisms of XRCC1 might be associated with overall survival period in patients with advanced NSCLC after treatment with platinumbased chemotherapy,which might be the predictive markers for overall survival.
出处
《实用老年医学》
CAS
2013年第11期897-899,907,共4页
Practical Geriatrics
基金
江苏省卫生厅科研项目(P200910)
关键词
单核苷酸多态性
非小细胞肺癌
铂类药物联合化疗
生存期
single nucleotide polymorphisms
non-small cell lung cancer
platinum-based combined chemotherapy
survival period
